Mindact Long-Term Results: 70-Gene Signature Mammaprint To Guide Adjuvant Chemotherapy Use In Br...

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in br...

Using MammaPrint to select patients who may not need adjuvant chemotherapy – the results of MINDACT

Mammaprint Blueprint, Updates from MINDACT 8.7 Year, & Applications in Neoadjuvant Therapy

Total Health | Oncology

Dr. Piccart on the MINDACT Study for Early-Stage Breast Cancer

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence

Results of the MINDACT clinical trial

Dr. Melisko Reflects on Findings From the MINDACT Trial in Breast Cancer

Researchers to present first outcome results from MINDACT breast cancer clinical trial

MammaPrint BluePrint Mindact Follow up data 8 years and Molecular Subtype

Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER

MINDACT Study Long Term Result Dr Fatima Cardoso

Practice-Changing Results from the MINDACT Trial

MammaPrint subt English

NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype

Introduction and Walkthrough: Summary of Results for MammaPrint and BluePrint

Updated findings on low-risk MINDACT participants reported | Laura van 't Veer

Medicine Matters oncology

Reshma Mahtani, DO | Sylvester Cancer | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage

Total Health | Oncology

Important lessons from TAILORX, MINDACT and RX-PONDER:

MammaPrint BluePrint Case Studies Jennifer Tittensor

The Use of Genomic MammaPrint BluePrint in Neoadjuvant Breast Cancer Dr James Pellicane